ArticleJournal of dual diagnosis2013
An Open Trial of Relapse Prevention Therapy for Smokers With Schizophrenia.
Article in Journal of dual diagnosis, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Relapse prevention interventions for smoking cessation.The Cochrane database of systematic reviews · 2019Pooled it
- Relapse prevention interventions for smoking cessation.The Cochrane database of systematic reviews · 2019Pooled it
- Combination Extended Smoking Cessation Treatment Plus Home Visits for Smokers With Schizophrenia: A Randomized Controlled Trial.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2017Trial
- Smoking Cessation in Individuals With Serious Mental Illness: A Randomized Controlled Trial of Two Psychosocial Interventions.Journal of dual diagnosis · 2015Trial
- Trial
- Reinstatement of nicotine conditioned place preference in a transgenerational model of drug abuse vulnerability in psychosis: Impact of BDNF on the saliency of drug associations.Psychopharmacology · 2023Article
- Psychological Experience of Smoking Addiction in Family and Friends of Schizophrenic Adults Who Smoke Daily: A Qualitative Study.Healthcare (Basel, Switzerland) · 2023Article
- Remission from nicotine dependence among people with severe mental illness who received help/services for tobacco/nicotine use.International journal of methods in psychiatric research · 2020Article
- Approved and emerging smoking cessation treatments for people with schizophrenia spectrum disorders: A narrative review.Health psychology research · 2020Article
- Tobacco smoking, related harm and motivation to quit smoking in people with schizophrenia spectrum disorders.Health psychology research · 2020Article
- Observational
- Predictors of tobacco abstinence in outpatient smokers with schizophrenia or bipolar disorder treated with varenicline and cognitive behavioral smoking cessation therapy.Addictive behaviors · 2017Article
- Achieving Smoking Cessation in Individuals with Schizophrenia: Special Considerations.CNS drugs · 2017Review
- Views and Preferences for Nicotine Products as an Alternative to Smoking: A Focus Group Study of People Living with Mental Disorders.International journal of environmental research and public health · 2016Article
- Smoking cessation and reduction in people with chronic mental illness.BMJ (Clinical research ed.) · 2015Review
- Smoking Use and Cessation Among People with Serious Mental Illness.The Yale journal of biology and medicine · 2015Review
- Behavioral Interventions for Individuals Dually-Diagnosed with a Severe Mental Illness and a Substance Use Disorder.Current addiction reports · 2014Article
- Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use Disorders.Current addiction reports · 2014Article
- Treatment of tobacco use disorders in smokers with serious mental illness: toward clinical best practices.Harvard review of psychiatryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveFollowing successful smoking cessation, smokers with schizophrenia are vulnerable to relapse shortly after treatment discontinuation. Our objective was to assess the feasibility and effectiveness of a 12-month relapse prevention intervention in recently abstinent smokers with schizophrenia.
methodAdult outpatient smokers with schizophrenia received weekly cognitive behavioral therapy groups, bupropion slow release, transdermal nicotine patch, and nicotine gum or lozenge for three months. Subjects with seven-day point prevalence abstinence at month 3 received an additional 12 months (months 4-15) of therapy with bupropion, transdermal nicotine patch, and nicotine gum/lozenge in conjunction with relapse prevention-based cognitive behavioral therapy groups that were held weekly in month 4, biweekly in months 5-6, and monthly in months 7-15.
resultsSeventeen of 41 participants (41.5%) attained biochemically verified self-report of seven-day point prevalence abstinence at the end of three months of treatment and entered relapse prevention treatment. There was an 81% attendance rate at relapse prevention groups. At the end of the 12-month relapse prevention phase (month 15 overall), 11 of 17 (64.7%) demonstrated biochemically verified seven-day point prevalence abstinence, and 10 of 17 (58.8%) reported four-week continuous abstinence. Almost one quarter of the sample (23.5%) demonstrated long-term prolonged abstinence through the end of the trial. There were no clinically detected cases of psychiatric symptom exacerbation. One participant, who was managed as an outpatient, self-reported psychiatric symptom exacerbation in the interim period between study visits.
conclusionsExtended duration smoking cessation treatment is well-tolerated and may improve smoking outcomes for recently abstinent smokers with schizophrenia. Controlled trials are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.